Core Insights - Freight Technologies, Inc. has successfully completed its first annual ISO 9001:2015 surveillance audit, reaffirming its commitment to quality assurance and continuous improvement in logistics services and transportation of goods in North America [1][2][4] Group 1: ISO Certification - The company has achieved ISO 9001:2015 certification for both its Mexico and US entities, validating its implementation of a Quality Management System (QMS) aimed at ensuring consistent service excellence [2][4] - ISO 9001:2015 is a globally recognized standard for quality management systems, providing a framework for enhancing operational efficiency and customer satisfaction [3] Group 2: Company Vision and Commitment - CEO Javier Selgas emphasized that the successful completion of the certification's annual audit represents a promise to clients for continued service excellence and innovation in the freight technology marketplace [5] - The achievement of ISO 9001:2015 certification for the second consecutive year aligns with the company's vision to revolutionize freight logistics through advanced technology and customer-focused solutions [5] Group 3: Company Overview - Freight Technologies offers a diverse portfolio of technology-driven solutions, including the Fr8App platform for cross-border shipping, Fr8Now for less-than-truckload shipping, and Zayren.ai, an AI-based pricing-prediction tool [6] - The company's interconnected solutions aim to optimize and automate the supply chain process, significantly improving operational efficiency through innovative technologies [6]

NORTH PALM BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced increasing its ownership in the common stock of Opendoor Technologies Inc., a leading digital platform for residential real estate transactions. The Company has also further reduced its short position across its cryptocurrency portfolio of Bitcoin and Ethereum and is now net long its holdings. Forward-Looking StatementsThis press release contains forward-looking statemen ...

Core Insights - Safe Pro Group Inc. has been awarded a $1,000,000 subcontract to supply AI processing systems to the U.S. Government through a prime contractor, indicating a significant business opportunity for the company in the defense sector [1] Company Overview - Safe Pro Group Inc. (NASDAQ: SPAI) specializes in AI-enabled security and defense solutions, providing advanced situational awareness tools for various applications including defense, humanitarian, and homeland security [4] - The company utilizes proprietary machine learning and computer vision technology to enhance drone imagery processing, allowing for rapid identification of explosive threats, which offers a safer alternative to traditional human analysis methods [4] - Safe Pro's platform is cloud-based and powered by Amazon Web Services (AWS), targeting multiple markets such as commercial, government, law enforcement, and humanitarian sectors [4] Strategic Partnerships - The internal development and low rate initial production (LRIP) for the awarded systems were funded through strategic investments from notable U.S. firms, including ONDAS Inc. and Unusual Machines Inc. [1]

Company Overview - ALK-Abelló A/S is a global specialty pharmaceutical company focused on allergy treatment, covering the entire value chain from development to marketing of products for diagnosing and treating respiratory allergies and severe allergic reactions [3]. Annual General Meeting - The Annual General Meeting of ALK-Abelló A/S is scheduled for Monday, 16 March 2026, at 4:00 PM (CET) in Hørsholm, Denmark [1]. - The agenda for the meeting includes complete proposals from the Board of Directors [1]. Employment and Market Presence - ALK employs approximately 2,700 people worldwide and is listed on Nasdaq Copenhagen under the ticker ALK B [3].

PHILADELPHIA, Feb. 20, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against BellRing Brands, Inc. (NYSE: BRBR) (“BellRing” or the “Company”) on behalf of investors who purchased or otherwise acquired BellRing securities during the period of November 19, 2024 through August 4, 2025 (the “Class Period”). Investor Deadline: Investors who purchased BellRing securities during the Class Period may, no later than March 23, 2026, seek ...

Core Insights - Senti Biosciences, Inc. is advancing its proprietary Gene Circuit platform for next-generation cell and gene therapies, participating in a Cell & Gene Live virtual event to discuss innovative cell therapy technologies [1][2][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing cell and gene therapies for incurable diseases, utilizing synthetic biology to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [6] Product Development - SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy designed to target CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while protecting healthy bone marrow cells [4] - The therapy includes an OR GATE for targeting cancer cells, a NOT GATE to protect healthy cells, and calibrated-release IL-15 to enhance cell persistence and activity [4] - Currently, Senti Bio is enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies in a Phase 1 clinical trial for SENTI-202, which may become a first-in-class allogeneic treatment for AML/MDS patients [4] Regulatory Designations - The FDA has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for treating relapsed/refractory hematologic malignancies, including AML [5]

Core Insights - ParaZero Technologies Ltd. has received an additional order for its DefendAir™ multi-layered Counter-UAS solution from a second branch of an Israeli defense entity, indicating growing trust in its technology [1][2][3] Group 1: Product Effectiveness - The new order highlights DefendAir's effectiveness, achieving 100% interception rates against high-speed threats, including FPV kamikaze drones and heavy-lift logistics platforms [2] - DefendAir features a non-explosive, patent-protected net-launching mechanism, providing a safe and cost-effective alternative to traditional counter-UAS methods [2] Group 2: Company Vision and Partnerships - The CEO of ParaZero expressed enthusiasm about deepening partnerships with Israeli defense entities, viewing the contract as validation of their innovative solutions that enhance national security [3] - The company aims to support more defense entities globally with its advanced systems and expert training [3] Group 3: Company Overview - ParaZero Technologies, founded in 2014, specializes in smart, autonomous solutions for the UAS industry, with a product portfolio that includes SafeAir, DefendAir, and DropAir [4] - The company's mission is to redefine aerial operations with intelligent systems that enhance safety, scalability, and security [4] Group 4: Additional Offerings - ParaZero offers specialized launchers for rapid deployment in various environments, enabling soft-kill interception of hostile drones with minimal collateral damage [6] - The company provides interception pods compatible with various configurations, ensuring layered defense for troops and critical infrastructure [6] - A comprehensive training package is available, including simulation-based and live-fire training modules to ensure operational readiness [6]

Core Insights - 20/20 BioLabs, Inc. is an early market leader in AI-powered laboratory-based blood tests for early detection and prevention of cancers and chronic diseases [3][5] - The company will host a virtual investor webinar on February 26, 2026, to discuss its recent Nasdaq listing and product offerings [4][5] - The company offers two main products: OneTest™ for Cancer™, a multi-cancer early detection blood test, and OneTest for Longevity™, which measures inflammatory biomarkers [5][6] Company Overview - 20/20 BioLabs was listed on Nasdaq under the ticker symbol "AIDX" on February 19, 2026 [5] - The company operates a CAP-accredited and CLIA-licensed laboratory in Gaithersburg, MD, where tests are conducted [6] - The company also runs a Clinical Laboratory Innovation Accelerator (CLIAx) to support overseas diagnostics start-ups [7] Upcoming Initiatives - The OneTest for Longevity™ is expected to launch before the end of February 2026 [4] - The virtual investor webinar will include a question-and-answer session, allowing investors to engage directly with the company's leadership [4][5]

Core Insights - Oncotelic Therapeutics Inc. has been featured in an editorial by BioMedWire, highlighting its strategic positioning within the biotechnology sector [1][2] Industry Trends - Biotechnology mergers and acquisitions are increasingly focused on clinical-stage and late-stage programs that are backed by human data, moving away from early discovery platforms with uncertain timelines [2] - Investors are now prioritizing assets that show safety signals, efficacy data, and clearer pathways to commercialization, indicating a shift in investment strategies within the sector [2] Company Overview - Oncotelic Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing oncology and immunotherapy products, particularly targeting high-unmet-need cancers and rare pediatric indications [4] - The company has expanded its international intellectual property coverage for its proprietary TGF-β antisense therapeutic platform, OT-101, enhancing its protection across neurology, oncology, and CNS drug-delivery technologies [3] - Oncotelic holds a 45% stake in GMP Bio, a joint venture that is advancing its own pipeline of drug candidates, further strengthening Oncotelic's strategic position in oncology and rare disease therapeutics [4]

Core Insights - CytoDyn Inc. is advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, with potential applications in metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC) [1][6] - New data presented at the AACR Immuno-Oncology Conference supports leronlimab's role in treating mTNBC, highlighting its ability to modulate immune checkpoint resistance and enhance responses to immune checkpoint inhibitors (ICIs) [2][5] Mechanistic Insights - Leronlimab targets the CCR5 receptor, which is crucial in regulating immune function and is implicated in cancer progression and immune resistance [2][6] - The study integrates patient-derived datasets with molecular and cellular analyses, suggesting that CCR5 blockade may influence T-cell exhaustion pathways and PD-L1/PD1 regulation, providing a rationale for combination therapies with ICIs [3][5] Clinical Findings - A pooled retrospective analysis of 28 heavily pretreated mTNBC patients showed a favorable safety profile for leronlimab, with no therapy-limiting toxicities and a 17.9% survival rate (5 out of 28 patients) after a median follow-up of over 63 months [6][5] - The data presented at the conference indicated that CCR5 expression correlates with elevated cytotoxic T-lymphocyte signatures and T-cell exhaustion profiles, suggesting immune states that may benefit from CCR5 inhibition [6] Future Directions - The consistency of mechanistic and clinical findings supports the continuation of leronlimab's clinical development, including further evaluation in combination immunotherapy settings [5][6] - CytoDyn is committed to improving patient quality of life through therapeutic innovation and aims to bring transformative treatments to patients worldwide [7]